California Public Employees Retirement System continued to hold its stake in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,200 shares of the biotechnology company’s stock at the end of the second quarter. California Public Employees Retirement System owned approximately 0.25% of Progenics Pharmaceuticals worth $1,169,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Progenics Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,300,478 shares of the biotechnology company’s stock valued at $29,200,000 after buying an additional 167,708 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Progenics Pharmaceuticals by 3.9% during the 2nd quarter. Northern Trust Corp now owns 895,458 shares of the biotechnology company’s stock worth $6,081,000 after purchasing an additional 33,774 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Progenics Pharmaceuticals during the 2nd quarter worth $983,000. Quantitative Investment Management LLC acquired a new stake in shares of Progenics Pharmaceuticals during the 2nd quarter worth $858,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Progenics Pharmaceuticals by 11.0% during the 2nd quarter. New York State Common Retirement Fund now owns 239,525 shares of the biotechnology company’s stock worth $1,626,000 after purchasing an additional 23,723 shares in the last quarter. 89.32% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently issued reports on the company. Zacks Investment Research lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reissued a “buy” rating and set a $15.00 target price on shares of Progenics Pharmaceuticals in a report on Thursday, November 2nd. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Needham & Company LLC reissued a “strong-buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. Finally, Aegis reissued a “buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Progenics Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $13.20.

ILLEGAL ACTIVITY NOTICE: “California Public Employees Retirement System Has $1,169,000 Holdings in Progenics Pharmaceuticals Inc. (PGNX)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dailypolitical.com/2017/11/10/california-public-employees-retirement-system-has-1169000-holdings-in-progenics-pharmaceuticals-inc-pgnx.html.

Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) opened at $5.69 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86. Progenics Pharmaceuticals Inc. has a 1 year low of $4.60 and a 1 year high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period in the prior year, the company earned $0.52 EPS. Progenics Pharmaceuticals’s revenue for the quarter was down 95.0% on a year-over-year basis. research analysts anticipate that Progenics Pharmaceuticals Inc. will post -0.92 earnings per share for the current fiscal year.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.